Bacterial microbiota of the upper respiratory tract and childhood asthma - 19/04/17
Abstract |
Background |
Patients with asthma and healthy controls differ in bacterial colonization of the respiratory tract. The upper airways have been shown to reflect colonization of the lower airways, the actual site of inflammation in asthma, which is hardly accessible in population studies.
Objective |
We sought to characterize the bacterial communities at 2 sites of the upper respiratory tract obtained from children from a rural area and to relate these to asthma.
Methods |
The microbiota of 327 throat and 68 nasal samples from school-age farm and nonfarm children were analyzed by 454-pyrosequencing of the bacterial 16S ribosomal RNA gene.
Results |
Alterations in nasal microbiota but not of throat microbiota were associated with asthma. Children with asthma had lower α- and β-diversity of the nasal microbiota as compared with healthy control children. Furthermore, asthma presence was positively associated with a specific operational taxonomic unit from the genus Moraxella in children not exposed to farming, whereas in farm children Moraxella colonization was unrelated to asthma. In nonfarm children, Moraxella colonization explained the association between bacterial diversity and asthma to a large extent.
Conclusions |
Asthma was mainly associated with an altered nasal microbiota characterized by lower diversity and Moraxella abundance. Children living on farms might not be susceptible to the disadvantageous effect of Moraxella. Prospective studies may clarify whether Moraxella outgrowth is a cause or a consequence of loss in diversity.
Le texte complet de cet article est disponible en PDF.Key words : Asthma, childhood, upper respiratory tract, throat, nose, microbiota, 16S rRNA gene
Abbreviations used : GABRIELA, OTU, OR, qPCR, 16S rRNA
Plan
This study was supported by the European Research Council (grant no. 250268) and the Wellcome Trust (grant no. 098051). |
|
Disclosure of potential conflict of interest: M. Depner receives grant support from the European Research Council and the German Research Foundation. M. J. Ege receives grant support from the European Research Council (grant no. 250268). J. Genuneit receives grant support from the European Commission (grant no. LSHB-CT-2006-018996). D. Heederik receives grant support from Utrecht University. E. von Mutius receives grant support from the European Research Council and the German Research Foundation; serves on the board for the American Academy of Allergy, Asthma & Immunology; serves as a consultant for System Analytic Ltd; provides expert testimony for University of Tampere, GBS RE HEFCE; receives payments for lectures from Ökosoziales Forum Oberösterreich, Mundipharma, HAL Allergie GmbH, DOC Congress SRL, American Thoracic Society, and Novartis Pharma; and receives personal fees from OM Pharma SA, AbbVie Deutschland GmbH & Co KG, and medUpdate GmbH. A. Legatzki receives grants from the European Research Council (grant no. 250268). The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 139 - N° 3
P. 826 - mars 2017 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?